source
- Silence Therapeutics’ Phase 2 Trial Shows Strong Efficacy of divesiran in Polycythemia VeraSilence Therapeutics reported that its siRNA candidate divesiran met the primary endpoint in a phase 2 study of patients with polycythemia vera. The trial enrolled 48 participants and 88% of those…
- Trump administration issues executive order questioning childhood vaccine scheduleThe White House unveiled a new executive order that challenges the established childhood vaccine schedule. President Trump announced the measure from the Oval Office, marking a shift after months o…